TherapeuticsMD (TXMD) Preferred Dividend Payments (2012 - 2013)
TherapeuticsMD's (TXMD) quarterly Preferred Dividend Payments came in at $1.1 million in Q2 2013, up 115.7% on a YoY basis from $488936.3 in Q2 2012, and up 115.7% quarter-over-quarter from -$6.7 million in Q2 2012.
Powered by 
Analysis
TherapeuticsMD (TXMD) Preferred Dividend Payments (2012 - 2013) Analysis & Trends
TherapeuticsMD (TXMD) has reported Preferred Dividend Payments for 2 consecutive years, with $1.1 million the latest figure, recorded in Q2 2013.
- For the quarter ending Q2 2013, Preferred Dividend Payments rose 115.7% year-over-year to $1.1 million; the trailing twelve-month figure through Jun 2013 stood at -$5.7 million (changed N/A YoY), and the FY2012 full-year result was -$6.7 million, changed N/A from the prior year.
- Preferred Dividend Payments climbed to $1.1 million in Q2 2013 per TXMD's latest filing, from -$6.7 million in the prior quarter.
- Across five years, Preferred Dividend Payments topped out at $1.1 million in Q2 2013 and bottomed at -$6.7 million in Q2 2012.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | - |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | - |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | - |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | - |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | - |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | - |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | - |
| 10 | TherapeuticsMD | 25.35 Mn | 16.16 Mn | - | - |